NCT07374419 Atamparib in Patients With Advanced Solid Tumors
| NCT ID | NCT07374419 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Nerviano Medical Sciences (Shanghai) Ltd. |
| Condition | NSCLC Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 178 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 178 participants in total. It began in 2026-03-18 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
Eligibility Criteria
Inclusion criteria: 1. Subject must be ≥18 years of age. 2. Histologically confirmed diagnosis of unresectable advanced or metastatic NSCLC adenocarcinoma. 3. Documented KRAS mutation status at study entry. 4. Have received at least one line of standard therapy and experienced radiographic tumor progression to the last administered treatment and have failed institutional standards of care. 5. Have measurable tumor lesions 6. ECOG 0-1 7. Adequate organ functions Exclusion criteria: 1. Non-adenocarcinoma histology of NSCLC. Patients whose tumors have a mixed histology are ineligible. 2. Wtih oncogenic driver mutation other than KRAS for which an approved therapy is available but not adequately treated. 3. Known active GI disease that would impact the absorption 4. Clinically significant cardiac disease 5. Requiring the administration of strong inhibitors or inducers of CYP3A4, P-gp or BCRP. 6. Symptomatic, or untreated CNS lesions.
Contact & Investigator
Caicun Zhou, Dr.
PRINCIPAL INVESTIGATOR
Shanghai East Hospital, Yuntailu 1800
Frequently Asked Questions
Who can join the NCT07374419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07374419 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07374419 currently recruiting?
Yes, NCT07374419 is actively recruiting participants. Contact the research team at olivia.chi@nervianoms.com for enrollment information.
Where is the NCT07374419 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07374419 clinical trial?
NCT07374419 is sponsored by Nerviano Medical Sciences (Shanghai) Ltd.. The principal investigator is Caicun Zhou, Dr. at Shanghai East Hospital, Yuntailu 1800. The trial plans to enroll 178 participants.